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Background: Sensory hyperreactivity (SHR) has been suggested as one explanation for chemi-
cally induced airway symptoms; it can be diagnosed with a capsaicin inhalation test. Previous
capsaicin inhalation studies of SHR have used a Pari Boy device. This model of inhalator
device has become outdated, hence it is necessary to abandon it in favour of a new device.
The aim of this study was to transfer the capsaicin inhalation test using the Pari Boy device
to a corresponding model using the Maxin MA3 device.
Methods: Twenty-one patients with SHR and 44 healthy controls visited the clinic twice and
underwent a randomised protocol. The participants were provoked with saline and capsaicin
using one of two devices, Pari Boy and Maxin MA3. Eight patients also underwent two addi-
tional capsaicin provocations with Maxin MA3. A new series of capsaicin concentrations was
chosen for Maxin MA3. The results from each device were analysed, the agreement between
the two devices and the repeatability of the Maxin MA3 were evaluated.
Results: Among all participants, the mean number of coughs with the Pari Boy was 5.5 (95%
CI: 2.7; 8.2) after inhalation of 0.4 mmol/L capsaicin and 20.0 (95% CI: 14.1; 25.9) after
2.0 mmol/L. With the Maxin MA3, the mean number of coughs was 3.6 (95% CI: 1.3; 4.0) after
0.06 mmol/L capsaicin, and 17.8 (95% CI: 12.0; 23.6) after 0.3 mmol/L. The Maxin MA3 showed
good repeatability and the agreement between the devices with the capsaicin concentrations
chosen for each device was considered to be good.
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In several earlier studies we have demonstrated increased
capsaicin cough sensitivity among a group of patients with
airway symptoms induced by chemicals and scents.1e10 One
possible explanation for these chemically induced.
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of the airways, or sensory hyperreactivity (SHR).1,3 SHR can
be diagnosed with a positive reaction to a capsaicin inhala-
tion test, with cut-off values according to Johansson et al.6
Capsaicin (8-methyl-N-vanillyl-6-nonenamide), the
ingredient that produces the heat in hot peppers
(Capsicum), is a well-known cough-inducing agent when
inhaled.11e14 It is a noxious and odourless vanilloid which
stimulates the nonmyelinated C-fibre endings of the
sensory nervous system and causes depolarisation across
the nerve cell membrane and a local release of neuropep-
tides.15 Inhaled capsaicin has long been used to induce
cough in a safe and dose-dependent manner, and the
degree of induced cough reflects the reactivity of sensory
C-fibres in the respiratory mucosa.11e13 Inhalation of capsa-
icin has good short- and long-term reproducibility.1,9,10,16,17
However, our earlier experiences have not only shown how
important it is that the chosen inhalation method should
produce a reproducible capsaicin induced cough, but also
demonstrated that various methods with different inhala-
tion devices induce different numbers of coughs.9
In these previous studies, capsaicin was inhaled by
a tidal breathing method, using the same inhalation device
(Pari Boy 36, type 37.0130 compressor and Pari Inhalier-
boy, no: 36.75 nebuliser; Paul Ritzau Pari-Werk GmbH,
Starnberg, Germany).1e10 In this method, different concen-
trations of capsaicin are inhaled through a mouthpiece and
the total number of coughs is counted over 10 min. Using
this device, we have developed a capsaicin inhalation test
and set up limits for the expected number of coughs to
identify patients with SHR.6 However, after several years
on the market, this model of inhalator device has become
outdated, and can no longer be purchased. Hence, it is
necessary to abandon this old device in favour of a new
and modern inhalation device, which is available on the
market and is easy to handle for both the patient and the
assisting nurse. The Maxin MA3 device is a well-known
piece of equipment which is common in a number of labo-
ratories in Sweden and has also been used in a variety of
inhalation studies.18e20
The aim of the present study was to transfer the
capsaicin inhalation test using the Pari Boy device to a cor-
responding model using the Maxin MA3 device.
Materials and methods
Patient group
The patient group consisted of 21 non-smoking patients (20
women and one man) aged between 30 and 67 years (mean
age 49 years). Each had a history of at least 2 years of upper
and lower airway symptoms induced by chemicals and
scents, and a positive capsaicin inhalation test adminis-
tered according to the method described by Johansson
et al.6 All patients had a negative skin-prick test (SPT)
result when tested with a standard panel of 10 allergens
common to Sweden. All patients except one had undergone
a methacholine test within the last five years. The metha-
choline test was performed in accordance with interna-
tional guidelines21 and was negative for all patients, with
two exceptions (PD20< 0.84). Two patients regularly usednasal steroids. The patients were asked to take no
medication for at least 4 h prior to the capsaicin inhalation
tests.
Control group
The control group consisted of 44 subjectively healthy
individuals (26 women and 18 men) aged between 19 and
64 years (mean age 47 years). They were subject to no
further medical examinations.
The participants were consecutively selected over
a period of about 6 months. Pregnancy or expected preg-
nancy, breastfeeding, and smoking were exclusion criteria.
Study design
Participants underwent a randomised protocol with two
capsaicin challenges on two different occasions, with at
least 1 week between the two occasions (range 1e10
weeks). The capsaicin challenges were performed with
one of two different air-driven devices, Pari Boy and Maxin
MA3. Each challenge comprised inhalation of saline fol-
lowed by two concentrations of capsaicin. The sequence
of the capsaicin concentrations was open, both to the study
subjects and to the nurse performing the tests. The number
of coughs was counted for 10 min from the start of each
inhalation provocation. Cough registration was performed
manually by the same counter for each participant in all
provocations. The total duration of each challenge was
approximately 35 min. Out of consideration for the partici-
pants, an upper cough limit was set; if a subject coughed 50
times or more at a given capsaicin concentration, provoca-
tion was stopped. Capsaicin inhalation was not performed
in subjects who had experienced respiratory infections in
the month prior to scheduled testing.
To evaluate the repeatability of the Maxin MA3 device,
eight of the 21 patients were randomised and underwent
two additional capsaicin provocations, at about 7- to 14-
day intervals between the two challenge occasions.
Informed consent was obtained from all participants at
the start of the investigation. The study was approved by
the Regional Ethical Review Board of Go¨teborg, Sweden.
Capsaicin solutions
A stock solution of capsaicin [SigmaeAldrich Sweden AB,
Stockholm; 1 mmol/L in ethanol (99.5%)] was prepared.10
For the Pari Boy device, aqueous provocation solutions
of 0.4 and 2.0 mmol/L were prepared from this stock solu-
tion in accordance with earlier studies.9,10 For the Maxin
MA3 device, aqueous provocation solutions of 0.06 and
0.3 mmol/L were chosen, following a pilot study.
In this pilot study, we tested groups of two or three
subjects with different concentrations of capsaicin with the
aim of finding plausible, comparable concentrations. Since
a series of fivefold capsaicin concentrations is used with the
Pari Boy device, a new number of fivefold series, with
different start concentrations, were set up for the Maxin
MA3 device and compared with the outcome of the Pari
Boy device. Initial capsaicin concentrations of 0.4 and
2.0 mmol/L resulted in far more coughs with the Maxin
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levels of 0.1 and 0.5 mmol/L also produced significantly
more coughs than desired. Capsaicin concentrations of
0.06 and 0.3 mmol/L seemed to produce results comparable
with those of the Pari Boy device, and hence these
concentrations were chosen for the actual study.
Capsaicin provocation with Pari Boy
Saline and the two increasing concentrations of capsaicin
(0.4 and 2.0 mmol/L) were administered by means of a Pari
Boy nebuliser. Each 1 mL concentration was inhaled
through a mouthpiece, without a nose-clip, by tidal volume
breathing to completion or for a maximum of 6 min. This
was followed by 4 min of rest. Before the provocation,
the nebuliser was moistened with 2 mL of saline using
a constant flow for 2 min (to completion) and then filled
with 1 mL provocation solution. 1,5,6,8e10 Technical specifi-
cations of the Pari Boy device are given in Table 1.
Capsaicin provocation with Maxin MA3
The provocation solutions were administered by means of
a Maxin MA3 nebuliser, which was filled with 2 mL saline
and two concentrations of capsaicin (0.06 and 0.3 mmol/
L). This device nebulises continually, produces a fine aero-
sol, has a reservoir for nebulised mist in a closed inhalation
system, and provides a fixed constant flow of 0.25 mL/min.
The participants were instructed to inhale with tidal
volume breathing without a nose-clip for 4 min, followed
by 6 min of rest, consequently inhaling a total of 1 mL of
provocation solution. Technical specifications of the Maxin
MA3 device are given in Table 1.
Lung function
At each study visit the forced expiratory volume during 1 s
(FEV1) was measured with one of three spirometers (Vitalo-
graph, Buckingham, UK; One Flow CC 1000, Clement Clarke
International Limited, England; Piko-6, Electronic FEV1/
FEV6 Meter. Ferraris Respiratory Europe Ltd, Hertford, UK)
before and after each capsaicin provocation. The highest
of three values was recorded.
Statistical analysis
Statistical analysis of the results obtained with the two
devices was carried out using the ManneWhitney U-test forTable 1 Technical specifications of the Pari Boy device and th
Methods
Pari Boy
Compressor Pari Boy 36, type 37.01.30 (Pau
Pari-Werk GmbH, Starnberg, Ge
Nebuliser Pari Inhalierboy, no: 36.75
Air flow rate 3.6 L/min
Nebuliser output 0.63 mL/min
Inhalation time 6 min
Mass median particle diameter 9.18 mmnon-paired data, and a paired t-test and the Wilcoxon
signed-rank test for paired data. Data are presented as
mean values with 95% confidence intervals (CIs), and a P
value of <0.05 was taken for statistical significance.
The agreement between the two devices and the
repeatability of the Maxin MA3 device were determined
using the method of Bland and Altman.22 In this method,
agreement is examined by a simple plot of the results of
one device against those of the other, and a plot of the
differences between the devices against their means.
Repeatability is determined by taking repeated measure-
ments of a series of subjects using the same technique.
The limits of agreement between the two methods and
coefficient of reproducibility are calculated as 2 standard
deviations (SDs) from the mean of the difference in
coughing.
Both inhalation methods were evaluated and compared
by constructing a ‘receiver operator characteristic curve
(ROC curve)’, in which sensitivity versus 1 specificity was
plotted for each possible cough cut-off level.23 The ROC
curve allows measurement of a method’s discriminative
ability, for example, the ability to distinguish two groups
from one another. An area under the curve of 0.5 suggests
no discriminative ability, while an area under the curve of
more than 0.90 indicates outstanding discriminative ability,
more than 0.80 indicates excellent discriminative ability,
and more than 0.7 indicates acceptable discriminative
ability.24
Results
Both the patients and the control subjects coughed dose-
dependently on each capsaicin concentration with both
inhalation devices. The patients coughed significantly more
than the control group for each capsaicin dose (P< 0.01),
whether administered by the Pari Boy or by the Maxin
MA3.
Capsaicin provocation with Pari Boy
All of the controls inhaled both concentrations of capsaicin.
One patient did not complete the provocation at the lower
concentration of capsaicin (0.4 mmol/L), because of more
than 50 coughs, and seven patients discontinued provoca-
tion at the higher concentration of capsaicin (2.0 mmol/L).
The mean number of coughs among all participants was
2.3 (95% CI: 0; 4.6) after inhaling saline, 5.5 (95% CI: 2.7;
8.2) after inhaling the lower concentration of capsaicine Maxin MA3 device
Maxin
l Ritzau,
rmany)
Maxin MA3 (Clinova Medical AB, Malmo¨, Sverige)
Maxin
4.5 L/min
0.25 mL/min
4 min
2.27 mm
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the higher concentration of capsaicin (2.0 mmol/L) (Fig. 1).
Capsaicin provocation with Maxin MA3
All of the controls inhaled both concentrations of capsaicin.
Among the patients, all completed the capsaicin inhalation
at the lower concentration of capsaicin (0.06 mmol/L), but
six discontinued provocation at the higher concentration
of capsaicin (0.3 mmol/L) due to having reached the limit
of more than 50 coughs.
The mean number of coughs among all participants was
0.9 (95% CI: 0; 2.1) after saline, 2.6 (95% CI: 1.3; 4.0) after
the lower concentration of capsaicin (0.06 mmol/L), and
17.8 (95% CI: 12.0; 23.6) after the higher concentration of
capsaicin (0.3 mmol/L) (Fig. 1).
Pari Boy versus Maxin MA3
The mean number of induced coughs after inhaling saline
did not differ between the two devices neither in the
control group nor among the patients. Both at the lower
concentrations of capsaicin (0.4 and 0.06 mmol/L) and at
the higher (2.0 and 0.3 mmol/L) the Maxin MA3 device
induced significantly less number of coughs (P< 0.05)
than the Pari Boy device among the control subjects. In
the patient group there were no significant differences
between the both devices (Table 2).
Agreement between the two devices
At the lower concentrations of capsaicin (0.4 and
0.06 mmol/L), the number of coughs, regarding the whole
group, correlated significantly between the two challenge
occasions (rZ 0.57, P< 0.001). The mean difference was
2.8 coughs (95% CI: 0.5; 5.1). The limits of agreement
between the two devices were 15.5 to 21 coughs (Fig. 2).
The corresponding number of coughs at the higher
concentrations of capsaicin (2.0 and 0.3 mmol/L) also corre-
lated significantly between the two challenge occasionsFigure 1 Mean number of coughs (95% CI) in 65 partici-
pants, after inhalation provocations with saline, lower capsa-
icin concentrations (0.4 and 0.06 mmol/L), and higher
capsaicin concentrations (2.0 and 0.3 mmol/L) using the Pari
Boy device and the Maxin MA3 device.(rZ 0.74, P< 0.001). The mean difference was 2.2 coughs
(95% CI: 2.0; 6.4). The limits of agreement between the two
devices were 31.8 to 36.2 coughs (Fig. 3).
Repeatability of the Maxin MA3 device
The two provocation series with the Maxin MA3 device in
eight patients did not differ significantly. At the higher
concentration of capsaicin (0.3 mmol/L), the number of
coughs correlated significantly between the two challenge
occasions (rZ 0.97, P< 0.001), but not at the lower capsa-
icin concentration (0.06 mmol/L) (rZ 0.63, P< 0.09). The
SD from the mean difference between the eight pairs of
repeated measurements was 7.4 coughs for the capsaicin
concentration of 0.06 mmol/L, and the coefficient of repro-
ducibility was thus calculated as 14.8 coughs. For 0.3 mmol/
L capsaicin, the corresponding values were 5 and 10 coughs,
respectively.
Ability to distinguish patients from control subjects
The ROC curves for the capsaicin provocations with both
devices and with the different capsaicin concentrations are
shown in Fig. 4. The area under the curve with the Pari
Boy device was 0.76 for 0.4 mmol/L capsaicin and 0.84
for 2.0 mmol/L capsaicin. The corresponding values with
the Maxin MA3 device were 0.80 for 0.06 mmol/L capsaicin
and 0.94 for 0.3 mmol/L capsaicin.
Effects of capsaicin inhalation on lung function
The mean value of FEV1 in the patient group was 96% (90;
103) of that predicted before the provocation with the
Pari Boy device. The corresponding value among the
healthy controls was 99% (96; 103). There were no differ-
ences in baseline FEV1 between the two challenge occa-
sions and there were no significant changes after the
capsaicin provocations among either the patients or the
healthy controls.
Discussion
In this study, we transferred a capsaicin provocation
method using the Pari Boy device to a corresponding
model using the Maxin MA3 device. Technical factors are
important for the cough outcome of a capsaicin inhalation;
for example, the diameter of the aerosol particles
produced by the nebuliser, the air flow rate, and the inspi-
ratory flow rate.25e27 Slow inhalation with small droplet
aerosol is known to cause more coughs from capsaicin
than rapid inhalation of large droplet aerosol.26,27 Since
the Maxin MA3 has sustainably higher air flow rate and
smaller particle size than the Pari Boy, a new series with
lower capsaicin concentrations was chosen for the Maxin
MA3 following a pilot study. We found that there was
good agreement between the results of inhaling capsaicin
with the two different series of capsaicin concentrations
chosen for each piece of equipment, and both methods
showed good ability to distinguish patients from healthy
control subjects.
Table 2 Results of capsaicin provocation, number of coughs (mean and 95% CI), with the Pari Boy device and the Maxin MA3
device, in patients with SHR and healthy controls
Group N
Capsaicin
Pari Boy Maxin MA3
0.4 mmol/L 2.0 mmol/L 0.06 mmol/L 0.3 mmol/L
Patients 21 13.3 [5.8; 20.9] 40.4 [26.3; 54.5] 6.8 [3.4; 10.1] 41.2 [29.8; 52.6]
Controls 44 1.7 [0.9; 2.6] 10.2 [7.3; 13] 0.6 [0; 1.3] 6.1 [3.0; 9.2]
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used for capsaicin cough challenge.28 The single-dose and
the doseeresponse challenge are the most common
methods described in the literature.29,30 In the single-
dose method, a single concentration of capsaicin is deliv-
ered. The doseeresponse challenge, on the other hand,
involves either administration of incremental concentra-
tions of capsaicin over a fixed time period, as described
herein, or administration of single breaths of incremental
concentrations of capsaicin. Both methods have been
demonstrated to be reproducible, with good reciprocal
agreement.31 Patients with SHR have an easily evoked
cough reflex and even inhalation of saline can induce
coughing.1,32 Using a single-dose provocation method to
decide the capsaicin concentration threshold that evoked
2, 5 or 10 coughs caused significant problems in earlier pilot
studies, hence we chose the doseeresponse method with
incremental concentrations of capsaicin over a fixed time
period. In our experience, this method of administering
inhalation of capsaicin and recording the total number of
coughs over 10 min at each concentration is a stable and
reproducible model.1,9,10 However, although capsaicin
challenge with the Pari Boy device has shown good repro-
ducibility, it has been associated with difficulties in loading
the nebuliser with just a small amount of liquid (1 mL),
difficulties with delivery of an accurate amount of capsa-
icin, and variations of dose delivery from the nebuliser.
These disadvantages, together with the problem of the
device having become outmoded and unavailable on the
market, made it necessary to look out for a new piece of
equipment.
Analyses of agreement between two methods on the
basis of correlation alone can be misleading, since resultsFigure 2 Differences between the two challenge occasions
against their mean number of coughs on inhalation of the lower
capsaicin concentrations (0.4 and 0.06 mmol/L).which correlate on a high level may still have large
between-method differences. When replacing an old
method with a new one, it is essential to know how much
the two methods differ from each other. Hence, we
calculated the agreement between the two inhalation
devices according to the recommendations of Bland and
Altman.22 In accordance with these guidelines, the agree-
ment between the Pari Boy and the Maxin MA3, with
the capsaicin concentrations chosen for each device, was
considered to be good. However, it is most unlikely that
two different methods will agree exactly. How much
a new method can differ from an old without becoming of
clinical importance is a matter of judgment.22 In the
present study the control subjects but not the patients
coughed less with the Maxin MA3 device in comparison
with the Pari Boy device. Regarding the generally mild
cough reactions among the controls in answer to all capsa-
icin provocations we consider these differences to be
without clinical significance.
Repeatability is relevant for assessing the agreement
between two methods. Capsaicin cough challenge with the
Pari Boy device has been performed by repeated measure-
ments in several other studies, and has shown a high degree
of reproducibility in healthy controls, asthmatic patients,
and patients with SHR.1,9 In the present study repeated
measurements in eight patients with the Maxin MA3 device
indicated a good reproducibility though the group is small.
The high correlation coefficient (rZ 0.97) at the strongest
concentration of capsaicin is in accordance with earlier
findings.9 One limitation of the present study may be that
the order of capsaicin concentrations was not randomised
or blinded but, on the basis of our earlier experience, the
order of doses has an influence on the cough results.8 ToFigure 3 Differences between the two challenge occasions
against their mean number of coughs on inhalation of the
higher capsaicin concentrations (2.0 and 0.3 mmol/L).
Figure 4 ROC curves of optimal cough cut-off levels to distin-
guish patients with SHR from healthy controls with the Pari Boy
device (capsaicin concentrations of 0.4 and 2.0 mmol/L) and the
Maxin MA3 device (capsaicin concentrations of 0.06 and
0.3 mmol/L).
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patients, healthy controls and in a longer perspective would
be of great interest in further research.
In investigating the extent to which different methods can
distinguish patients from healthy control subjects, it can be
useful to construct an ROC curve. A large area under the
curve indicates that a method has a good ability to distinguish
patients from healthy control subjects. Both devices used in
this study had acceptable discriminative ability at the lowest
concentrations of capsaicin (0.4 and 0.06 mmol/L). For the
highest concentrations of capsaicin, the area under the curve
indicated excellent discriminative ability for the Pari Boy
(at 2.0 mmol/L) and outstanding discriminative ability for
the Maxin MA3 (at 0.3 mmol/L). Overall, the Maxin MA3
showed a higher degree of discriminative ability than the
Pari Boy device at both capsaicin concentrations. The fact
that the Maxin MA3 device induced just few coughs among
the healthy controls may be one explanation for the higher
discrimination ability for this device.
In conclusion, we found that with the recommended
capsaicin concentrations, the two inhalation devices inves-
tigated in this study can be used interchangeably to
estimate levels of neural sensory reactivity. However, the
Maxin MA3 device seems preferable because it provides
better accuracy of delivered capsaicin, a smaller variation
in dose delivery, and a higher degree of discrimination
ability, in comparison to the Pari Boy device. Another
advantage of the Maxin MA3 device is that it places no
demands on the patients’ ability to manoeuvre the equip-
ment, since the air flow rate is fixed and does not depend
on any participation other than tidal breathing.
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